Funding momentum Nanite has secured multiple funding rounds including a $6M seed and a $2M financing round, indicating investor confidence and potential for partnerships or pilot programs that align with their AI-driven gene delivery platform.

Therapeutic focus Active exploration of genetic medicines for cystic fibrosis and collaboration with organizations focused on Charcot-Marie-Tooth disease suggests opportunities to cross-sell platform capabilities to researchers and biotech firms targeting lung delivery and neuropathic conditions.

AI driven delivery SAYER platform combines AI and high-throughput experimentation to design programmable polymer nanoparticles, presenting a compelling value proposition for pharma and biotech companies seeking faster, tissue-specific gene delivery solutions.

Non-viral expertise Specialization in non-viral gene delivery may appeal to firms aiming to mitigate viral vector risks; potential sales angles include partnerships for safer, scalable gene therapy research and development programs.

Strategic collaborations Current ecosystem includes partnerships with CF Foundation and CMTRF, signaling openness to collaborative programs; leverage these relationships to propose co-development, grant-aligned pilots, or sponsored research engagements.